2095 Survival benefit, safety, and prognostic factors for outcome with Regorafenib (RE) in patients (pts) with pretreated metastatic colorectal cancer (mCRC). Main analyses of the REBECCA study

Fontaniere, C. De La Fouchardiere; Paule, B.; Burtin, P; Wallet, J.; Tougeron, D.; Dourthe, L.M.; Etienne, P.L.; Mineur, L.; Becuwe, C.; Maes, P.; Dauba, J.; Michel, P.; Wendling, J.L.; Linot, B.; Hollebecque, A.; Clisant, S.; Morere, J.F.; Andre, T.; Phelip, J.M.; Adenis, A.

期刊名称European Journal of Cancer
作者Fontaniere, C. De La Fouchardiere; Paule, B.; Burtin, P; Wallet, J.; Tougeron, D.; Dourthe, L.M.; Etienne, P.L.; Mineur, L.; Becuwe, C.; Maes, P.; Dauba, J.; Michel, P.; Wendling, J.L.; Linot, B.; Hollebecque, A.; Clisant, S.; Morere, J.F.; Andre, T.; Phelip, J.M.; Adenis, A.
卷第51卷
印刷ISSN0959-8049
文件大小59.74KB
发表时间2015-09
DOI10.1016/s0959-8049(16)31017-6

发现好书期刊，享受阅读乐趣

2095 Survival benefit, safety, and prognostic factors for outcome with Regorafenib (RE) in patients (pts) with pretreated metastatic colorectal cancer (mCRC). Main analyses of the REBECCA study